Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVRA contraceptive patch NGMN and EE · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE |
| Name | Type | Description |
|---|---|---|
| EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE | DRUG | - |
Inclusion Criteria: * Subjects who are not pregnant (as demonstrated by negative pregnancy tests at screening and before admission for each treatment period) and who have completed their last term pregnancy at least 60 days before the admission visit * confirmed to be in good health as determined b...
EVRA is a transdermal contraceptive patch containing norelgestromin (NGMN) and ethinyl estradiol (EE). It is worn on the skin to deliver hormones for contraception. The patch is developed by Johnson & Johnson, which trades under the ticker JNJ, and it falls within the endocrine therapeutic area as a small molecule product.
EVRA contraceptive patch NGMN and EE is used for contraception in women. It delivers norelgestromin and ethinyl estradiol through the skin to prevent pregnancy. The clinical program recorded in public registries lists contraception and female contraception as the studied conditions, and enrolled participants were female adults aged 18 years and older.
Johnson & Johnson, ticker JNJ, is the developer of the EVRA contraceptive patch NGMN and EE. The company is listed as the sponsor behind the clinical development program for this transdermal contraceptive patch containing norelgestromin and ethinyl estradiol.
EVRA contraceptive patch NGMN and EE is at the Phase 1 stage of clinical development based on the registered trial record. It is an investigational asset in this dataset rather than a marketed product, and the single registered study has completed. No active trials are currently listed for this patch.
One registered trial covers EVRA contraceptive patch NGMN and EE: NCT00258076, titled A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch). It was a Phase 1, randomized, uncontrolled study that completed with 53 enrolled female participants aged 18 years and older.